Centiva Capital’s Keros Therapeutics KROS Stock Holding History

Centiva Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-90,000	Closed	-$1.22M	–	1828
2025 Q1	$917K	Buy	+90,000	New	+$1.04M	0.03%	539

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Centiva Capital's KROS Position: Q2 2025 in Review

Centiva Capital sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 90,000 shares — an estimated $1.22M sold.

Centiva Capital first reported a position in KROS in Q1 2025 and held it in 1 quarter. The position peaked at $917K in Q1 2025. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

Centiva Capital reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
Centiva Capital sold 90,000 Keros Therapeutics shares in Q2 2025, an estimated $1.22M.
Centiva Capital first reported a position in Keros Therapeutics in Q1 2025 and held it in 1 quarter.
Centiva Capital's Keros Therapeutics position peaked at $917K in Q1 2025.
139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.